Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

pembrolizumab 24Paclitaxel 11Carboplatin 11Trastuzumab 9Nivolumab 7Fulvestrant 6palbociclib 4olaparib 4Taxes 4Surveys and Questionnaires 4Methods 4Early Intervention, Educational 4Docetaxel 4Cyclophosphamide 4Biopsy 4Bevacizumab 4pertuzumab 3lenvatinib 3fludarabine 3atezolizumab 3abemaciclib 3Tamoxifen 3Specimen Handling 3Psychiatric Rehabilitation 3Metformin 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interviews as Topic 3Gemcitabine 3Counseling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × CYH33 × Breast × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡